Unlocking Legalities: Ninth Circuit Allows Wider Range Of False Claim Suits
Executive Summary
The Ninth Circuit Court of Appeals allowed False Claims Act allegations against drug manufacturers Gilead Sciences to move forward despite a US Supreme Court ruling last year that raised FCA standards.
You may also be interested in...
Appeals Court Rejects False Claims Approach To FDA Off-Label Cases
A ruling from the First Circuit suggests that plaintiffs can’t prove manufacturers violated the False Claims Act by suggesting FDA submissions were fraudulent, if FDA itself hasn’t taken any action against the manufacturer.
FCA Liability After Escobar: Challenges And Opportunities For Device Companies
A recent Supreme Court decision addressing the False Claims Act holds important implications for medical device companies, according to Gibson Dunn attorneys John D. W. Partridge, Jonathan M. Phillips and Reid F. Rector in this guest column.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.